4-(benzyloxy)cyclopentane-1,2-diol | 1083419-72-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(benzyloxy)cyclopentane-1,2-diol
• 英文别名: 4-phenylmethoxycyclopentane-1,2-diol
• CAS: 1083419-72-0
• 化学式: C₁₂H₁₆O₃
• 分子量: 208.257
• InChiKey: YDAOZTMWAJQOGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(benzyloxy)cyclopentane-1,2-diol 在 盐酸 、 sodium periodate 作用下， 以 水 为溶剂， 反应 25.5h， 生成 (1R,5S,7r)-9-benzyl-7-(benzyloxy)-9-azabicyclo[3.3.1]nonan-3-one
  参考文献：
  名称：

  Design and Synthesis of Diazatricyclodecane Agonists of the G-Protein-Coupled Receptor 119

  摘要：

  A series of GPR119 agonists based on a 2,6-diazatricyclo[3.3.1.1 similar to 3,7,similar to]decane ring system is described. Also provided is a detailed account of the development of a multigram scale synthesis of the diazatricyclic ring system, which was achieved using a Hofmann-Loffler-Freytag reaction as the key step. The basis for the use of this complex framework lies in an attempt to constrain one end of the molecule in the "agonist conformation" as was previously described for 3-oxa-7-aza-bicyclo[3.3.1]nonanes. Optimization of carbamate analogues of the diazatricylic compounds led to the identification of 32i as a potent agonist of the GPR119 receptor with low unbound human liver microsomal clearance. The use of an agonist response weighted ligand lipophilic efficiency (LLE) termed AgLLE is discussed along with the issues of applying efficiency measures to agonist programs. Ultimately, solubility limited absorption and poor exposure reduced further interest in these molecules.

  DOI：

  10.1021/jm301626p
• 作为产物：
  描述：

  4-苄氧基环戊烯 在 三乙烯二胺 、 四氧化锇 、 水 、 potassium carbonate 、 potassium hexacyanoferrate(III) 作用下， 以 叔丁醇 为溶剂， 反应 18.0h， 以73.8%的产率得到4-(benzyloxy)cyclopentane-1,2-diol
  参考文献：
  名称：

  Concise Total Synthesis of (−)-Deoxocuscohygrine and (−)-Dihydrocuscohygrine

  摘要：

  GraphicsThe concise enantioselective total synthesis of C(2)-asymmetrical (-)-deoxocuscohygrine and (-)-dihydrocuscohygrine are described. Double-diastereoselective additions of normal Grignard reagent to bis(1.3-oxazolidine) have been deployed to construct chiral diamine fragments as a key step.

  DOI：

  10.1021/jo801700f

文献信息

• A new approach to all—cis triquinane synthesis and a new route to the C16—hexaquinane system
  作者：Philip E. Eaton、Ravinder S. Sidhu、Gordon E. Langford、David A. Cullison、Cornel L. Pietruszewski

  DOI：10.1016/0040-4020(81)80015-4

  日期：1981.1

  A new synthesis of all-cis triquinanes is presented. The examples bear a cis substituent on the fifth position of the central ring, and are thus all-cis pentasubstituted cyclopentanes. The stereo-controlled addition of organometallics of 7-ketonorbornenes is considered, as is “reductive solvolysis” of such adducts to the corresponding hydrocarbons. The preparation of trans-3,4-dimethoxycyclopentyl

  提出了一种新的全顺式三喹烷合成方法。实例在中心环的第五位带有顺式取代基，因此是全顺式五取代的环戊烷。认为是立体控制的7-酮基降冰片烯有机金属的加成，以及这种加合物向相应烃类的“还原溶剂化”。给出了反式-3,4-二甲氧基环戊基氯的制备方法，以及相应的有机锂的制备方法。举例来说，可以考虑在羟醛型反应中使用喹喔啉衍生物。开发了一种新的C 16-六喹烷体系方法。报告的环系统包括：tricyclo- [8.2.1.0 2,9]十三烷，三环[6.3.0.0 3,7 ]十一烷，四环[10.1.0.0 2,9 0.0 10,13 ]十三烷，五环[8.5.1.0 2,6 0.0 7,16 0.0 11,15 ]己烯和六环（8.5.1.0 2,6 .0 3,14 .0 7,16 .0 11,15 ]十六烷。
• Ethylenediamine derivatives
  申请人：——

  公开号：US20040122063A1

  公开（公告）日：2004-06-24

  The invention relates a compound represented by the formula (1): Q 1 -Q 2 -C(═O)—N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 ( 1 ) wherein R 1 and R 2 represent H or the like; Q 1 represents an aromatic ring, heterocyclic ring or the like; Q 2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q 3 represents a group 1 or the like, Q 4 represents an aromatic ring, heterocyclic ring or the like; and T 1 represents —CO— or —SO 2 —, and a medicine which comprises the compound and is useful for thrombosis and embolism.

  本发明涉及一种由式（1）表示的化合物：Q1-Q2-C(═O)—N(R1)-Q3-N(R2)-T1-Q4(1)，其中R1和R2代表H或类似物；Q1代表芳香环，杂环或类似物；Q2代表单键，芳香环，杂环或类似物；Q3代表群1或类似物，Q4代表芳香环，杂环或类似物；T1代表—CO—或—SO2—，以及包含该化合物并对治疗血栓和栓塞有用的药物。
• Monoacylated 1,2-diaminocycloalkanes
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP2431370A1

  公开（公告）日：2012-03-21

  Compounds represented by the following general formula (9): The compounds (9) are synthetic intermediates of pharmacologically active products.

  以下通式(9)所代表的化合物： 化合物（9）是药理活性产品的合成中间体。
• ETHYLENEDIAMINE DERIVATIVES
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1270557B1

  公开（公告）日：2012-07-25
• METHODS AND COMPOSITIONS FOR MODULATING SPLICING
  申请人：Skyhawk Therapeutics, Inc.

  公开号：EP3921311A1

  公开（公告）日：2021-12-15